Radicava: What is Radicava? Details

What is Radicava and How Does It Work for ALS

Radicava (edaravone) as an FDA-approved neuroprotective agent for ALS

Radicava (edaravone) is the first new FDA-approved treatment for amyotrophic lateral sclerosis (ALS) in many years, cleared specifically as a neuroprotective agent for this progressive disease. [1] ALS destroys the nerve cells that control voluntary muscles -- affecting movement, speech, swallowing, and breathing -- and the CDC estimates that 12,000-15,000 Americans are living with ALS at any given time. [1] Edaravone acts as a free radical scavenger, reducing the oxidative stress that damages and kills nerve cells, which is why understanding [how ALS medications work](https://alsunited.org/blog/mechanisms-of-als-medications) can help patients and caregivers ask better questions during neurology appointments. [1] The FDA also granted Radicava orphan drug designation, which provides development incentives for therapies targeting rare diseases like ALS. [1]

The mechanism of action: How edaravone slows disease progression

Edaravone works by scavenging free radicals -- unstable molecules that damage neurons by attacking proteins, lipids, and DNA, a process called oxidative stress that drives motor neuron death in ALS. [3] It neutralizes both hydroxyl and peroxyl radicals, reducing cellular damage before it becomes irreversible. [3] Edaravone also activates the Nrf2 signaling pathway, which triggers the body's own antioxidant defense enzymes -- including heme oxygenase-1 (HO-1) -- providing a layer of protection that extends beyond direct radical neutralization. [3] In ALS mouse models, edaravone slowed motor neuron degeneration and reduced mutant SOD1 protein buildup in the spinal cord, offering preclinical evidence of how this mechanism may translate to slowing disease progression in people. [3]

Clinical evidence from pivotal trials showing slowed decline in ALS patients

The pivotal phase 3 trial (MCI-186-J19) was a 24-week, randomized, double-blind, placebo-controlled study measuring functional decline via the ALSFRS-R scale, which tracks daily activities like speech, swallowing, and limb movement. [4] Patients on edaravone lost 2.49 fewer ALSFRS-R points than those on placebo, and three times as many treated patients lost two or fewer points (39.1% vs. 13.2%). [4] Post-hoc analyses of the same study examined how distinct disease progression trajectories responded to treatment, supporting the consistency of edaravone's effect across different patient subgroups. [5] A 48-week observational analysis against PRO-ACT historical controls extended this evidence across geographically and ethnically diverse North American, European, and Asian populations, with treated patients losing 8.4 ALSFRS-R points versus 14.1 in controls -- though these findings are considered exploratory given the retrospective design. [4]

Radicava Administration Methods: Comparing Intravenous and Oral Options

Intravenous Radicava: Dosing schedule, infusion protocol, and patient experience

Intravenous Radicava delivers a 60 mg dose -- two consecutive 30 mg IV bags -- over 60 minutes at approximately 1 mg per minute. [7] The dosing cycle starts with daily infusions for 14 consecutive days in the first month, followed by a 14-day break, then shifts to 10 infusion days per 14-day period in subsequent months, each followed by another 14-day drug-free interval. [6] Infusions can be given at home once the initial sessions are completed in a clinical infusion center, which reduces the scheduling burden for patients and caregivers over the long course of treatment. [6] Other medications cannot be added to the infusion bag, and the solution must be used within 24 hours of opening its overwrap packaging. [7]

Radicava ORS (oral solution): Once-daily dosing and convenience benefits

Head-to-head comparison table: IV vs. oral administration for ALS patients Choosing between IV and oral edaravone for ALS depends on four practical factors: efficacy, convenience, side effect profile, and lifestyle impact. Both formulations follow identical 28-day dosing cycles, and the FDA approved Radicava ORS based on pharmacokinetic data confirming comparable blood levels to the IV form -- meaning the efficacy established in the pivotal phase 3 trial carries over to both routes. [10] The table below maps each dimension so you and your care team can identify which format fits your current disease stage and daily routine. [11]

| Factor | Radicava IV | Radicava ORS (oral) | |---|---|---| | **Efficacy** | 33% slowing of ALSFRS-R decline, established in phase 3 trial [10] | Equivalent efficacy; FDA approval based on pharmacokinetic matching to IV blood levels [10] | | **Convenience** | Initial infusions required at a clinic or infusion center; home infusion available after first sessions [10] | Fully self-administered at home; no clinic visits or infusion equipment required [11] | | **Side effect profile** | Sodium bisulfite in formulation; risk of allergic reactions, including anaphylaxis [10] | Same sodium bisulfite content; identical allergy and anaphylaxis risk profile [10] | | **Lifestyle impact** | 60-minute infusion sessions per dose; 14 daily doses in cycle one, then 10 doses per subsequent cycle [10] | Morning fasting required; water-only for 1 hour post-dose; same 28-day cycle structure [10] |

Choosing the Right Radicava Administration Method for Your ALS Care Plan

How to work with your neurology team to evaluate which method suits your needs

When evaluating which edaravone route fits your needs, your neurology team will assess factors that shaped the original clinical trial criteria: lung function (FVC of at least 70%), time since diagnosis, and mobility -- all of which affect whether IV infusion remains practical. [12] The IV formulation requires consistent infusion center access, and for patients with advancing limitations, the travel burden often shifts the conversation toward oral Radicava ORS. [12] Bring specific questions to each appointment -- ask about your current ALSFRS-R trajectory and how your caregiver's availability fits a 10-to-14-day dosing cycle. [12] Working with a [neuromuscular specialist or ALS neurologist](https://alsunited.org/blog/what-type-of-doctor-treats-als-understanding-als-medical-care) gives you the clearest picture of which administration method aligns with your clinical profile and daily routine. [12]

Key factors: Disease stage, mobility, caregiver support, and treatment goals

Disease stage and mobility are the most direct factors: patients with advancing limb weakness or swallowing changes may find oral Radicava ORS more practical, since it can be administered via feeding tube when swallowing becomes difficult. [8] Caregiver availability also shapes the decision -- home IV infusion requires someone trained to set up and monitor the process, while ORS requires only confirming the overnight fast before morning administration. [13] Treatment goals, specifically whether reducing clinic visits or maintaining a consistent care routine matters most, should anchor the final discussion with your neurology team, and [caregiver preparation resources](https://alsunited.org/blog/for-caregivers-families) can help families plan which format remains sustainable as needs change. [8]

ALS United's medical resources and clinic finder services to connect you with specialists

Once you've identified which edaravone route fits your clinical profile, connecting with a specialized ALS center helps ensure treatment administration and broader care coordination work together. There are more than 200 ALS clinics across the U.S., and the ALS Geospatial Hub's clinic finder maps accredited centers so patients and families can locate one nearby. [14] Multidisciplinary ALS centers coordinate referrals across physical therapy, speech therapy, nutritional counseling, and psychological support -- reducing the burden of managing multiple providers independently. [15] Our [care services](https://alsunited.org/blog/our-care-services) include ALS support specialists reachable by phone at 866.942.6257 or by email, ready to help connect you with clinical resources, answer treatment questions, and identify local services. [14]

Managing Radicava Treatment: Side Effects, Monitoring, and Ongoing Support

Common side effects of edaravone and what to expect with each administration route

The most common edaravone side effects across both formulations are contusion, gait disturbance, and headache -- none of which are specific to one administration route. [16] The IV formulation carries additional risks tied to catheter use, including blood clots in the line, collapsed veins, and swelling or infection at the insertion site. [17] Both IV and oral forms contain sodium bisulfite, so the risk of serious allergic reactions -- including anaphylaxis -- applies regardless of which route you use, and any signs of rapid breathing, irregular heartbeat, hives, or facial swelling require immediate medical attention. [16] Real-world FAERS data covering 2017 through early 2024 identified unexpected side effects not listed on the label, including liver problems, blood clots, and infection, with most reports occurring within the first month of treatment and a median onset of 16 days after starting -- findings that researchers note require further investigation given the voluntary nature of adverse event reporting. [17]

How to administer Radicava safely and recognize when to contact your care team

Before each IV infusion, check the solution for particles or discoloration and do not use it if either is present; once the overwrap packaging is opened, the solution expires after 24 hours. [18] Never add other medications to the infusion bag, and always use the provided syringe -- not a household spoon -- when giving Radicava ORS by mouth or feeding tube. [12] If a dose is missed, contact your doctor or pharmacist right away for a revised schedule rather than attempting to make up the dose on your own. [18] Go to the nearest emergency room or call your care team immediately if you experience hives, swelling of the lips, tongue, or face, fainting, difficulty breathing, wheezing, trouble swallowing, dizziness, or an asthma attack -- all of which can signal a serious allergic reaction requiring urgent attention. [12]

Building your ALS support network: Counseling, community events, and local services through ALS United

Support groups and counseling are practical tools for managing the sustained emotional demands that come with ALS treatment and caregiving. Groups led by licensed facilitators -- including clinical psychologists, social workers, and nurses -- give patients, caregivers, and family members a structured space to process shared experiences and reduce isolation. [20] If depression or anxiety begins to affect daily functioning, your primary care doctor or mental health professional can recommend counseling, medication, or both, depending on your symptoms. [19] Our [virtual support groups](https://alsunited.org/blog/join-a-support-group) cover a range of needs -- from sessions for the newly diagnosed to caregiver-only groups, young adults, and bereavement -- so there is a relevant space no matter where you are in the ALS journey. [20]